Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Jul;35(7):1469–1473. doi: 10.1128/aac.35.7.1469

Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group.

J R Groothuis 1, M J Levin 1, W Rodriguez 1, C B Hall 1, C E Long 1, H W Kim 1, B A Lauer 1, V G Hemming 1
PMCID: PMC245192  PMID: 1718213

Abstract

Infants with cardiopulmonary disease develop severe illness from respiratory syncytial virus (RSV) infection. Safety, feasibility, and pharmacokinetics of intravenous gamma globulin (IVIG) to prevent RSV illness were studied in 23 high-risk infants in a phase I trial. IVIG with an RSV neutralizing antibody titer of 1:1,100 in 5% solution was given monthly over a 2- to 4-h period in a clinical setting during the RSV season. The first group (n = 7) received 500 mg/kg of body weight, the second group (n = 9) received 600 mg/kg, and the third group (n =7) received 750 mg/kg. Serum was drawn prior to infusion and 2, 14, and 30 days after infusion. Total immunoglobulin G and RSV A2 and RSV B neutralizing antibody levels were obtained after the first IVIG infusion. Two children developed mild reversible pulmonary edema (group receiving 600 mg/kg per dose), and one developed hives and wheezing during one infusion (group receiving 500 mg/kg per dose). Twelve children developed subsequent RSV infection during two RSV seasons (November to April) over a 2-year follow-up period; 9 of 12 developed infection during the infusion year. Eleven illnesses were mild; one child died of progressive RSV illness (group receiving 500 mg/kg per dose). A cumulative infusion effect was not observed. IVIG appears safe and feasible in an outpatient setting, and at 750 mg/kg per dose, a target RSV antibody level of greater than or equal to 1:100 was achieved.

Full text

PDF
1473

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abman S. H., Ogle J. W., Butler-Simon N., Rumack C. M., Accurso F. J. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr. 1988 Nov;113(5):826–830. doi: 10.1016/s0022-3476(88)80008-8. [DOI] [PubMed] [Google Scholar]
  2. Brandt C. D., Kim H. W., Arrobio J. O., Jeffries B. C., Wood S. C., Chanock R. M., Parrott R. H. Epidemiology of respiratory syncytial virus infection in Washington, D.C. 3. Composite analysis of eleven consecutive yearly epidemics. Am J Epidemiol. 1973 Nov;98(5):355–364. doi: 10.1093/oxfordjournals.aje.a121565. [DOI] [PubMed] [Google Scholar]
  3. Chirico G., Rondini G., Plebani A., Chiara A., Massa M., Ugazio A. G. Intravenous gammaglobulin therapy for prophylaxis of infection in high-risk neonates. J Pediatr. 1987 Mar;110(3):437–442. doi: 10.1016/s0022-3476(87)80514-0. [DOI] [PubMed] [Google Scholar]
  4. Coates H. V., Alling D. W., Chanock R. M. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol. 1966 Mar;83(2):299–313. doi: 10.1093/oxfordjournals.aje.a120586. [DOI] [PubMed] [Google Scholar]
  5. Conway S. P., Dear P. R., Smith I. Immunoglobulin profile of the preterm baby. Arch Dis Child. 1985 Mar;60(3):208–212. doi: 10.1136/adc.60.3.208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fulginiti V. A., Eller J. J., Sieber O. F., Joyner J. W., Minamitani M., Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 1969 Apr;89(4):435–448. doi: 10.1093/oxfordjournals.aje.a120956. [DOI] [PubMed] [Google Scholar]
  7. Glezen P., Denny F. W. Epidemiology of acute lower respiratory disease in children. N Engl J Med. 1973 Mar 8;288(10):498–505. doi: 10.1056/NEJM197303082881005. [DOI] [PubMed] [Google Scholar]
  8. Glezen W. P., Paredes A., Allison J. E., Taber L. H., Frank A. L. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr. 1981 May;98(5):708–715. doi: 10.1016/s0022-3476(81)80829-3. [DOI] [PubMed] [Google Scholar]
  9. Glezen W. P., Taber L. H., Frank A. L., Kasel J. A. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986 Jun;140(6):543–546. doi: 10.1001/archpedi.1986.02140200053026. [DOI] [PubMed] [Google Scholar]
  10. Green M., Brayer A. F., Schenkman K. A., Wald E. R. Duration of hospitalization in previously well infants with respiratory syncytial virus infection. Pediatr Infect Dis J. 1989 Sep;8(9):601–605. doi: 10.1097/00006454-198909000-00007. [DOI] [PubMed] [Google Scholar]
  11. Groothuis J. R., Gutierrez K. M., Lauer B. A. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics. 1988 Aug;82(2):199–203. [PubMed] [Google Scholar]
  12. Groothuis J. R., Salbenblatt C. K., Lauer B. A. Severe respiratory syncytial virus infection in older children. Am J Dis Child. 1990 Mar;144(3):346–348. doi: 10.1001/archpedi.1990.02150270096033. [DOI] [PubMed] [Google Scholar]
  13. Groothuis J. R., Woodin K. A., Katz R., Robertson A. D., McBride J. T., Hall C. B., McWilliams B. C., Lauer B. A. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J Pediatr. 1990 Nov;117(5):792–798. doi: 10.1016/s0022-3476(05)83347-5. [DOI] [PubMed] [Google Scholar]
  14. Hall C. B., Kopelman A. E., Douglas R. G., Jr, Geiman J. M., Meagher M. P. Neonatal respiratory syncytial virus infection. N Engl J Med. 1979 Feb 22;300(8):393–396. doi: 10.1056/NEJM197902223000803. [DOI] [PubMed] [Google Scholar]
  15. Hall C. B., Powell K. R., MacDonald N. E., Gala C. L., Menegus M. E., Suffin S. C., Cohen H. J. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986 Jul 10;315(2):77–81. doi: 10.1056/NEJM198607103150201. [DOI] [PubMed] [Google Scholar]
  16. Hemming V. G., Prince G. A., Horswood R. L., London W. J., Murphy B. R., Walsh E. E., Fischer G. W., Weisman L. E., Baron P. A., Chanock R. M. Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model. J Infect Dis. 1985 Nov;152(5):1083–1087. doi: 10.1093/infdis/152.5.1083. [DOI] [PubMed] [Google Scholar]
  17. Kapikian A. Z., Mitchell R. H., Chanock R. M., Shvedoff R. A., Stewart C. E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969 Apr;89(4):405–421. doi: 10.1093/oxfordjournals.aje.a120954. [DOI] [PubMed] [Google Scholar]
  18. Kyllonen K. S., Clapp D. W., Kliegman R. M., Baley J. E., Shenker N., Fanaroff A. A., Berger M. Dosage of intravenously administered immune globulin and dosing interval required to maintain target levels of immunoglobulin G in low birth weight infants. J Pediatr. 1989 Dec;115(6):1013–1016. doi: 10.1016/s0022-3476(89)80761-9. [DOI] [PubMed] [Google Scholar]
  19. MacDonald N. E., Hall C. B., Suffin S. C., Alexson C., Harris P. J., Manning J. A. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med. 1982 Aug 12;307(7):397–400. doi: 10.1056/NEJM198208123070702. [DOI] [PubMed] [Google Scholar]
  20. McMillan J. A., Tristram D. A., Weiner L. B., Higgins A. P., Sandstrom C., Brandon R. Prediction of the duration of hospitalization in patients with respiratory syncytial virus infection: use of clinical parameters. Pediatrics. 1988 Jan;81(1):22–26. [PubMed] [Google Scholar]
  21. Mills J., 5th, Van Kirk J. E., Wright P. F., Chanock R. M. Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J Immunol. 1971 Jul;107(1):123–130. [PubMed] [Google Scholar]
  22. Noya F. J., Rench M. A., Garcia-Prats J. A., Jones T. M., Baker C. J. Disposition of an immunoglobulin intravenous preparation in very low birth weight neonates. J Pediatr. 1988 Feb;112(2):278–283. doi: 10.1016/s0022-3476(88)80070-2. [DOI] [PubMed] [Google Scholar]
  23. Ogilvie M. M., Vathenen A. S., Radford M., Codd J., Key S. Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol. 1981;7(4):263–271. doi: 10.1002/jmv.1890070403. [DOI] [PubMed] [Google Scholar]
  24. Prince G. A., Hemming V. G., Horswood R. L., Chanock R. M. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res. 1985 Oct;3(3):193–206. doi: 10.1016/0168-1702(85)90045-0. [DOI] [PubMed] [Google Scholar]
  25. Prince G. A., Horswood R. L., Camargo E., Koenig D., Chanock R. M. Mechanisms of immunity to respiratory syncytial virus in cotton rats. Infect Immun. 1983 Oct;42(1):81–87. doi: 10.1128/iai.42.1.81-87.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Prince G. A., Horswood R. L., Chanock R. M. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol. 1985 Sep;55(3):517–520. doi: 10.1128/jvi.55.3.517-520.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Prince G. A., Jenson A. B., Hemming V. G., Murphy B. R., Walsh E. E., Horswood R. L., Chanock R. M. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol. 1986 Mar;57(3):721–728. doi: 10.1128/jvi.57.3.721-728.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES